Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects With Newly Diagnosed Metastatic Renal Cell Carcinoma (Stage IV)

Phase 2

Suspended

• Conditions: Carcinoma, Renal Cell; Kidney Neoplasms

• Registration Number: NCT00065572
• Lead Sponsor: AstraZeneca

Brief Summary

The purpose of this study is to assess the biological activity of ZD6126 in subjects with newly diagnosed metastatic renal cell carcinoma (stage IV).

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2003-07-28
• Study First Submitted QC: 2003-07-30
• Study First Posted: 2003-07-31
• Study Start: 2003-08
• Primary Completion: 2004-02
• Study Completion: 2004-02
• Status Verified: 2011-01
• Last Update Submitted: 2011-01-25
• Last Update Posted: 2011-01-26

Recruitment & Eligibility

• Status: SUSPENDED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Newly diagnosed metastatic renal cell carcinoma
• Suitable for nephrectomy

Exclusion Criteria

• Prior chemotherapy, biological therapy or radiation therapy for renal cell carcinoma or within the last 3 years for any other cancer
• Significant cardiac event within 3 months of entry
• Any history of coronary angioplasty or history of myocardial infarction

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Trial Locations

Locations (1)

Research Site; 🇺🇸 Salt Lake City, Utah, United States